clinical significant uncontrolled disease

Use of intranasal corticosteroids (\<4 weeks of FP \[branded or generic\],\<4 week exposure to FF, \<4 weeks use of other INS)

Use of intranasal medications \<1 week

Use of meds that significantly inhibit CYP4503A4

Use of perfume or oral rinse on study day

Allergy/intolerance to INS, antihistamines, or excipients

Positive pregnancy test or female who is breastfeeding

Affiliation with investigational site

Fluticasone Nasal Spray Patient Preference Study